Status:
RECRUITING
Cardiac Injury Due to Anthracycline in Paediatric Oncological Patients
Lead Sponsor:
IRCCS Burlo Garofolo
Conditions:
Heart Injuries
Anthracycline
Eligibility:
All Genders
Up to 18 years
Brief Summary
The study investigates the role of echocardiography and of serum biomarkers (NT-proBNP, cardiac Troponin-I) in predicting cardiac injury in a cohort of paediatric oncological patients treated with Ant...
Detailed Description
Anthracycline chemotherapy (AC) can cause dose-related cardiomyocyte injury and death, possibly leading to left ventricular dysfunction. The most commonly accepted pathophysiological mechanism of anth...
Eligibility Criteria
Inclusion
- Paediatric oncological patients 0-18 years
- Planned start of anthracycline therapy
- Normal left ventricular systolic function according to International Guidelines before the treatment with AC
Exclusion
- Previous anthracycline treatment, bone marrow transplantation or chest radiation
- Pre-anthracycline treatment echocardiographic evidence of:
- More than mild pericardial effusion
- More than mild mitral regurgitation
- Poor echocardiographic acoustic window
Key Trial Info
Start Date :
July 21 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
July 21 2033
Estimated Enrollment :
22 Patients enrolled
Trial Details
Trial ID
NCT06898320
Start Date
July 21 2023
End Date
July 21 2033
Last Update
May 9 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
IRCCS Burlo Garofolo
Trieste, Italy, Italy, 34137